Earnings call transcript: Aedifica posts strong H1 2026 growth after Cofinimmo merger

Aedifica reported H1 2026 EPRA EPS of EUR 2.71 (+5% YoY) and a 62% YoY jump in rental income, attributing the improvement to the Cofinimmo merger being EPS-accretive from day one. The company reaffirmed full-year 2026 EPRA EPS guidance at EUR 5.35 while targeting at least EUR 16m of run-rate synergies by 2027 (EUR 5.0–5.5m in 2026), alongside normalized care-home occupancy returning to 91%. Debt metrics were highlighted (average cost of debt 1.9%, debt-to-asset 42.7%, net debt/EBITDA 8.3x) and refinancing capacity was discussed as management prepared for EUR 2.2bn refinancing in 2027–2028; shares were little changed (-0.22%) to $67.75, suggesting investors were encouraged but cautious given leverage and regulatory/divestment items.

Analysis

The market is treating the operating beat as confirmation, not a catalyst, which is why the equity barely budged. The real upside is not the merger math; it is the ability to recycle non-core assets into higher-yielding healthcare capital before the 2027 refinancing wall arrives. That creates a second-order winner set: private buyers of Belgian care-home and Brussels office assets may get forced-seller pricing without public-market headline risk.

The main risk is balance-sheet compression, not occupancy. Today’s synergy benefit can be swallowed quickly if the autumn bond clears wider than management assumes or if the asset-sale timeline slips, because every extra spread point raises the hurdle for NAV accretion and reduces the value of “accretive from day one” rhetoric. Over the next 1-3 months, the stock likely trades on funding headlines and divestment progress; over 6-18 months, it trades on whether leverage can stay anchored while growth capital is redeployed at attractive spreads.

Contrarian view: consensus is overrating the certainty of synergies and underweighting the fact that the earnings bridge to 2027 still depends on regulatory patience in Belgium and a functioning private market for the disposals. The more interesting long-term call is that Belgium eventually has to permit more resident pricing flexibility, which would expand operator coverage and lift rent durability across the sector. Until that shows up in actual policy or realized sale pricing, this is a slow compounding story rather than a momentum rerating.

Key Decisions for Investors

• Start/maintain a starter long in AEDFF on weakness rather than chasing the print; use $65-$66 as the add zone and look for a 6-12 month move toward the low-$70s if divestments and refinancing stay on schedule.
• Pair trade: long AEDFF / short GPE.L (or a European office REIT basket) to isolate the higher-quality cash flow and de-risking path from office-market and refinancing beta.
• Put AEDFF on a catalyst watch ahead of the autumn bond; if the new issue prices meaningfully wider than management’s implied assumption or if debt/asset trends above 43.5% before the 2027 asset-sale window, reduce exposure.
• Treat CCOOF only as a corporate-action technical, not a standalone fundamental long; avoid adding unless there is clear, liquid arb residual in the merger spread.